EUCTR2010-018275-20-NL进行中（未招募）不适用
A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion
niversity Medical Centre Nijmegen St Radboud0 个研究点目标入组 32 人开始时间: 2010年1月8日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-symptomatic malignant ascites and/or pleural effusion (from a histological proven solid malignancy which is refractory to standard anti-tumour therapy of for which no standard therapy exists)
- •-Karnofsky score = 50 % if the low performance score is due to ascites and/or pleural effusion, otherwise = 60 %
- •-age = 18 years
- •-written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Contraindications for treatment with cediranib:
- •-the presence of a pleural or peritoneal tap
- •-Untreated unstable brain or meningeal metastases..
- •-Previous treatment with chemotherapeutic agents or tyrosine kinase inhibitors (TKIs) within 14 days prior to the first dose of cediranib, with cetuximab within 30 days prior to the first dose of cediranib, or with bevacizumab within 60 days prior to the first dose of cediranib
- •-Inadequate bone marrow reserve as demonstrated by an absolute neutrophil count =1.5 x 109/L or platelet count =100 x 109/L
- •-Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 2,5 x ULN
- •-Serum creatinine > 1.5 x ULRR or a creatinine clearance of = 50mL/min calculated by the MDRD equation
- •-Greater than +1 proteinuria on two consecutive dipsticks taken no less than 1 week apart unless urinary protein < 1.5g in a 24 hr period
- •-Prothrombin time (PT) and activated partial thromboplastin time (APTT) > 2 x ULN, History of significant gastrointestinal impairment, as judged by the Investigator, that would significantly affect the absorption of cediranib, including the ability to swallow the tablet whole. Patients with an ileostoma.
- •-Patients with a history of poorly controlled hypertension with resting blood pressure >150/100 in the presence or absence of a stable regimen of anti-hypertensive therapy. Patients who are currently receiving maximal doses of calcium channel blockers or more than 1 antihypertensive for the treatment of hypertension are also ineligible.
- •-Any evidence of severe or uncontrolled diseases e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease.
- •-Unresolved toxicity > CTC grade 1 from previous anti-cancer therapy (including radiotherapy) except alopecia (if applicable) or polyneuropathie.
- •-Mean QTc with Bazetts correction >470msec in screening ECG or history of familial long QT syndrome
- •-Significant haemorrhage (>30mL bleeding/episode in previous 3 months) or haemoptysis (>5mL fresh blood in previous 4 weeks)
- •-Recent (<14 days) major surgery prior to entry into the study, or a surgical incision that is not fully healed
- •-Pregnant or breast-feeding women or women of childbearing potential with a positive pregnancy test prior to receiving study medication
- •-Known risk of the patient transmitting HIV, hepatitis B or C via infected blood
- •-Treatment with an investigational (non-registered) drug within 30 days prior to the first dose of cediranib
- •-Other concomitant anti-cancer therapy (including LHRH agonists) except steroids
- •-Concomitant use of any medication that may significantly affect hepatic cytochrome P450 drug metabolising activity by way of enzyme induction (e.g., phenytoin) or inhibition (e.g., ketoconazole, ritonavir, erythromycin) within 2 weeks if the first dose of cediranib and throughout the study period
- •-Patients being treated with anticoagulants (with the exception of low molecular weight heparin).
研究者
相似试验
招募中
2 期
A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusioexcess fluid in the pleural cavityperitoneal cavity fluid10027655NL-OMON35120niversitair Medisch Centrum Sint Radboud32
进行中（未招募）
不适用
A clinical trial of a drug called Cediranib in the treatment of patients with a type of cancer called alveolar soft part sarcomaMedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Alveolar soft part sarcomaMedDRA version: 14.1Level: HLTClassification code 10001883Term: Alveolar soft part sarcomasSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021163-33-ESThe Institute of Cancer Research / The Royal Marsden NHS Foundation Trust36
进行中（未招募）
不适用
A Randomised Phase II Study Evaluating Cediranib vs. Cediranib and Saracatanib in patients with relapsed metastatic clear cell renal cancer - COSAKEUCTR2009-018014-20-GBCommon Services Agency130
招募中
2 期
A trial of cediranib in the treatment of patients with alveolar soft part sarcomaAlveolar soft part sarcomaACTRN12612000020886The Institute of Cancer Research / Royal Marsden Hospital NHS Foundation Trust (UK)36
已完成
2 期
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial CancerEndometrial AdenocarcinomaEndometrial Adenosquamous CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Serous AdenocarcinomaRecurrent Uterine Corpus CarcinomaNCT01132820National Cancer Institute (NCI)53